摘要
Abstract
Objective To investigate the effects of different doses of rosuvastatin on ventricular remodeling in treating the acute myocardial infarction ( AMI ) patients without percutaneous coronary intervention ( PCI ). Methods 112 normal lipi-demia AMI patients without PCI were randomly divided into three groups: ( 1 ) routine treatment group ( control group ): being treated with conventional drugs such as aspirin, clopiclogrel, nitrate and p - blocker; ( 2 ) conventional - dose rosuvastatin group: taking 10 mg/d rosuvastatin before sleep in addition to routine therapy; ( 3 ) large - dose rosuvastatin group: taking 20 mg/d rosuvastatin before sleep in addition to routine therapy. The levels of hs - CRP, MMP-9, BNP and LVEDD, LVESD, LVEDV, LVESV, LVEF were all measured after 1 - week and 16 - week treatment of AMI. Results After one week of treatment , in terms of biochemical indexes and ultrasonic heartbeat graph indexes, no significant difference was found in the three groups ( P > 0. 05 ); After 16 weeks of treatment, compared with those in routine treatment group and conventional - dose rosuvastatin group, the levels of hs-CRP, MMP-9, BNP and LVEDD, LVESD, LVEDV, LVESV, LVEF in large - dose rosuvastatin group were all decreased significantly, and ultrasonic heartbeat graph index was also improved obviously. The differences were all significant among the three groups and between 1 -week and 16 -week ( P <0. 05 ). Conclusion Our results suggested that rosuvastatin could delay the proceeding of atherosclerosis, inhibit ventricular remodeling, improve heart function and long - term prognosis. And its effect could be further strengthened by increasing the doses of rosuvastatin.关键词
瑞舒伐他汀/心肌梗死/心室重构/血管成形术,经皮冠状动脉Key words
Rosuvastatin/Myocardial infarction/Ventricular remodeling/Angioplasty,percutaneous coronary分类
医药卫生
